Edict Acquisition (Schedule Of Acquisition-Date Fair Value Of The Consideration Transferred) (Details) (Edict Acquisition [Member], USD $) In Thousands, unless otherwise specified	Mar. 31, 2012		Feb. 17, 2012
Edict Acquisition [Member]
Business Acquisition [Line Items]
Cash paid for equity	$ 20,659
Contingent purchase price liabilities	11,641	[1]
Cash paid for assumed indebtedness	4,300
Total consideration	$ 36,600		$ 36,600

[1] Contingent purchase price liabilities represent subsequent milestone payments related to successful FDA inspection of the Par Formulations manufacturing facility and ANDA filings. All contingent purchase price liabilities are expected to be paid within 18 months of the acquisition date.